Cagrilintide: Dosage, Benefits & Research Guide
Also known as: AM833, long-acting amylin analog
What is Cagrilintide?
Cagrilintide is a long-acting acylated amylin analogue engineered for extended receptor engagement at the amylin receptor complex (AMY1 and AMY3). Its mechanism involves activating calcitonin and amylin receptors in the area postrema and hypothalamus, modulating satiety signaling and gastric emptying. In the REDEFINE 1 phase 3 trial (Lau et al., published 2023), cagrilintide 2.4 mg administered weekly demonstrated statistically significant weight reduction compared to placebo over 68 weeks. Notably, Novo Nordisk's CagriSema program combines cagrilintide with semaglutide, and phase 2 data (REDEFINE 2) showed the combination achieved greater weight reduction than either agent alone, suggesting synergistic effects between amylin and GLP-1 receptor pathways. Compared to pramlintide, the only previously available amylin analogue, cagrilintide offers a substantially longer half-life (approximately 7 days vs. hours), enabling once-weekly dosing in research protocols. Research also indicates potential benefits in alcohol-related liver disease models, where amylin signaling may reduce hepatic lipid accumulation. The lyophilized powder should be stored at -20C prior to reconstitution with sterile water or bacteriostatic water; reconstituted solutions should be refrigerated at 2-8C. This compound is primarily studied by obesity research institutes, pharmaceutical laboratories investigating incretin-amylin synergy, and academic centers focused on appetite neurobiology and hepatic metabolism.
Cagrilintide Research Applications
In published and preclinical research, Cagrilintide has been studied across the following areas:
- Obesity and type 2 diabetes management studies
- Synergistic weight loss research with semaglutide
- Liver injury and alcohol-related liver disease research
- Cardiovascular condition exploration
Cagrilintide in Research: Reconstitution & Study Concentrations
Cagrilintide is a long-acting amylin analog studied alone and in combination with semaglutide (CagriSema) in published clinical research. In the laboratory the lyophilized peptide is reconstituted with bacteriostatic water; working concentration depends on the assay. Cagrilintide is not FDA-approved and is supplied for research use only.
Worked example: a 10mg vial reconstituted with 2 mL of bacteriostatic water yields 5.00 mg/mL.
Open the reconstitution calculatorHow Cagrilintide Compares
Researchers frequently evaluate Cagrilintide alongside related compounds:
- Cagrilintide vs Retatrutide — different metabolic mechanism